CEN Danwei,SONG Yiling,ZHANG Chanqiong, et al. Prokaryotic expression of recombinant PE38KDEL protein and preparation of its polyclonal antibody[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2017, 47(1): 1-6.
Abstract:Objective: To prepare PE38KDEL recombinant protein from Pseudomonas exotoxin A in prokaryotic expression system and prepare the PE38KDEL specific polyclonal antibody. Methods: The C-terminal 609-613 amine acid REDLK from Pseudomonas aeruginosa exotoxin (PE) genes (PE38) was mutanted to KDEL. After prokaryotic codon optimization (http://www.jcat.de), the full gene sequences were synthesized and then cloned into expression vector pET32a (+) prokaryotic expression vector inserted into Hind III and Xho I and constructed the recombinant plasmid pET32a (+)/PE38KDEL. After sequenced, the plasmid was transformed into E.coli BL21 (DE3) and induced by isopropyl beta-D-1-thiogalactoside (IPTG) to get the PE38KDEL protein. The recombinant protein was purified by Ni-NTA affinity chromatography, SDS-PAGE and Western blot were used to identify it. Then, the rabbits were immunized by the PE38KDEL purified protein. The sera were collected before and after immunized. The antibody reaction and titer were detected by ELISA. Results: The pET32a (+)/PE38KDEL recombinant plasmid was successfully constructed and the protein was expressed and purified in the prokaryotic expression system. The protein molecular weight was about 57 kDa which was in accordance with the expected theoretical value. The PE38KDEL polyclonal antibody was obtained by immunization of rabbits and the titer of it was as high as 1:60 000. Conclusion: The PE38KDEL recombinant protein can induce the rabbit to produce serum polyclonal antibody which has high titer and strong specificity and can be used for further study which laid a solid foundation on the biology and immunology function.
[1] MICHALSKA M,WOLF P. Pseudomonas exotoxin A: optimized by evolution for effective killing[J]. Front Microbiol, 2015, 6: 963.
[2] VALLERA D A. Gene therapy with immunotoxins[J]. Methods Mol Biol, 2001, 166: 235-246.
[3] 祁志荣. PE类重组免疫毒素的研究进展[J]. 微生物学免疫学进展, 2006, 34(1): 50-53.
[4] XIONG W B, HUANG N, FENG Y, et al. Creation and anticancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III[J]. Chin Med J (Engl), 2008, 121(1): 82-95.
[5] KENNEDY P E, BERA T K, WANG Q C, et al. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques[J]. J Leukoc Biol,2006, 80(5): 1175-1182.
[6] LI M,WANG B, WU Z, et al. Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells[J]. Tumour Biol, 2015, 36(10): 7961-7966.
[7] LI M, WANG B, WU Z, et al. A novel recombinant protein of ephrinA1-PE38/GM-CSF activate dendritic cells vaccine in rats with glioma[J]. Tumour Biol, 2015, 36(7): 5497-5503.
[8] KAWAKAMI K, TERABE M, KIOI M, et al. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors[J]. Clin Cancer Res, 2006, 12(15): 4678-4686.
[9] GEBHARDT M M, EBERLE K E, RADTKE P, et al. Baculovirus resistance in codling moth is virus isolate-dependent and the consequence of a mutation in viral gene pe38 [J]. Proc Natl Acad Sci U S A, 2014, 111(44): 15711-15716.
[10] LIU H, SEIJSING J, FREJD F Y, et al. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2: 2 891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain[J]. Int J Oncol, 2015, 47(2): 601-609.
[11] BRINKMANN U, PAI L H, FitzGerald D J, et al. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice[J]. Proc Natl Acad Sci U S A, 1991, 88(19): 8616-8620.
[12] STACHYRA A, REDKIEWICZ P, KOSSON P, et al. Codon optimization of antigen coding sequences improves the immune potential of DNA vaccines against avian influenza virus H5N1 in mice and chickens[J]. Virol J, 2016, 13(1): 143-153.
[13] BOYCHEVA S, CHKODROV G, IVANOV I. Codon pairs in the genome of Escherichia coli[J]. Bioinformatics, 2003, 19(8): 987-998.
[14] 蔡海莺, 李杨, 张辉, 等. 基因设计对重组蛋白表达的影响研究进展[J]. 生物工程学报, 2013, 29(9): 1201-1213.
[15] KREITMAN R J. Recombinant immunotoxins for the treatment of chemo resistant hematologic malignancies[J]. Curr Pharm Des, 2009, 15(23): 2652-2664.
[16] PIASCIK P. FDA approves fusion protein for treatment of lymphoma[J]. J Am Pharm Assoc (Wash), 1999, 39(4): 571-572.
[17] Bao X, Chandramohan V, Reynolds R P. Preclinical toxicity evaluation of a novel immunotoxin D2C7-(scdsFv)-PE38KDEL administered via intracerebral convection-enhanced delivery in rats[J]. Invest New Drugs, 2016, 11(1): 1-10.
[18] 徐悦玥, 蔡冉, 马颖, 等. 肺炎链球菌表面蛋白A的原核表达、纯化及其多克隆抗体的制备[J]. 中国生物制品学杂志, 2015, 28(4): 372-382.
[19] 王冰冰, 涂建欣, 吕艳, 等. HPV16型E7重组蛋白的表达及其多克隆抗体的制备[J]. 细胞与分子免疫学杂志, 2014,30(2): 167-175.
[20] 贾慧娜, 罗海玲. 多克隆抗体制备方法的研究进展[J]. 中国草食动物科学, 2012, S1: 66-69.